Correlation between primary versus secondary resistance and progression pattern (n=166)
| Progression pattern | Resistance type | ||
| Primary resistance (n=123) | Secondary resistance (n=43) | P value | |
| General progression pattern | <0.001 | ||
| Enlargement only | 34 (28) | 7 (16) | |
| New lesion(s) only | 19 (15) | 23 (54) | |
| Both | 70 (57) | 13 (30) | |
| No of involved organ(s) | <0.001 | ||
| 1 | 49 (40) | 31 (72) | |
| 2 | 39 (32) | 11 (26) | |
| >=3 | 35 (28) | 1 (2) | |
| LDH at PD | 0.005 | ||
| Normal | 48 (39) | 24 (56) | |
| Elevated | 67 (54) | 12 (28) | |
| NA | 8 (7) | 7 (16) | |
| Target lesion size at PD (mm)* | 64.0 (0 to 415.0) | 29.2 (0 to 229.0) | <0.001 |
| Tumor enlargement dynamics† | |||
| Percent change from last evaluation (%) | 31.3 (−100.0 to 241.0) | 3.3 (−71.4 to 120.0) | 0.001 |
| Percent change from last evaluation (%) per month | 13.2 (−28.6 to 82.2) | 0.8 (−14.6 to 109.1) | 0.001 |
| LDH elevation dynamics‡ | |||
| Percent change from last evaluation (%) | 12.3 (−33.7 to 354.6) | 2.1 (−25.4 to 42.6) | 0.003 |
| Percent change from last evaluation (%) per month | 13.3 (−49.7 to 409.2) | 2.4 (−36.3 to 41.7) | 0.003 |
*Thirteen patients with no available target lesion size data at PD.
†18Eighteen patients with no available tumor enlargement dynamics data.
‡Twenty-four patients without LDH dynamics data at PD.
LDH, lactate dehydrogenase; NA, not available; PD, disease progression.